CMS has reached agreements with bluebird bio and Vertex Pharmaceuticals for their FDA-approved gene therapies for sickle cell disease — Casgevy and Lyfgenia, respectively. Under the Cell and Gene Therapy Access Model, CMS will tie payments for the therapies to their effectiveness in improving health outcomes for Medicaid recipients, according to a Dec.

CMS已与bluebird bio和Vertex Pharmaceuticals就其FDA批准的镰状细胞病基因疗法达成协议，分别为卡奇维和利夫吉尼亚。根据一份12月的报告，在细胞和基因治疗获取模式下，CMS将把治疗费用与改善医疗补助受者健康状况的有效性联系起来。

4 news release from the agency. The program aims to increase access to these treatments, reduce healthcare costs and improve patient outcomes. Sickle cell disease affects more than 100,000 people in the U.S., with more than half of those who are enrolled in Medicaid. The model will launch in January 2025, allowing states to participate between January 2025 and January 2026. .

4该机构发布的新闻稿。该计划旨在增加获得这些治疗的机会，降低医疗保健成本并改善患者预后。镰状细胞病影响了美国10多万人，其中一半以上的人参加了医疗补助。该模型将于2025年1月推出，允许各州在2025年1月至2026年1月之间参与。